Jesse L Berry1,2, Kaitlin Kogachi1,2, Hassan A Aziz1,2, Kathleen McGovern2, Emily Zolfaghari2, A Linn Murphree2, Rima Jubran3, Jonathan W Kim1,2. 1. USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California. 2. The Vision Center at Children's Hospital Los Angeles, Los Angeles, California. 3. The Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: The purpose of this study was to evaluate the risk of metastatic disease and orbital recurrence in advanced retinoblastoma treated with systemic chemoreduction versus primary enucleation. METHODS: A retrospective review of patients with Group D/E retinoblastoma was conducted with data collection from 1995 to 2015. Overall, 345 eyes (294 patients) were included (165 Group D and 180 Group E). Primary outcome measures were orbital recurrence and metastatic disease. RESULTS: Of the 345 eyes, 139 were treated with systemic chemoreduction (102 Group D, 37 Group E) and 206 with primary enucleation (63 Group D, 143 Group E). In the chemoreduction group, one patient developed metastasis (0.7%) and one an orbital recurrence (0.7%). In the primary enucleation group, two patients developed metastases (0.9%) and one an orbital recurrence (0.5%). After systemic chemoreduction, 58 of the 139 eyes (30 Group D, 28 Group E) were secondarily enucleated for treatment failure (41.7%). The median time to secondary enucleation from diagnosis was 8.1 months. None of the eyes in the systemic chemoreduction group had high-risk pathologic features. In the primary enucleation group, 56 eyes had high-risk pathology. CONCLUSION: Over a 20-year period, 345 eyes were treated for advanced retinoblastoma at Children's Hospital Los Angeles. Incidence of orbital recurrence and metastatic disease was <1% and did not vary by treatment modality or group classification. None of the eyes enucleated for treatment failure had high-risk pathology, and none of these patients developed metastatic disease. Globe salvage therapy with systemic chemoreduction and subsequent enucleation for poor response does not increase the risk of metastatic disease or orbital recurrence.
BACKGROUND: The purpose of this study was to evaluate the risk of metastatic disease and orbital recurrence in advanced retinoblastoma treated with systemic chemoreduction versus primary enucleation. METHODS: A retrospective review of patients with Group D/E retinoblastoma was conducted with data collection from 1995 to 2015. Overall, 345 eyes (294 patients) were included (165 Group D and 180 Group E). Primary outcome measures were orbital recurrence and metastatic disease. RESULTS: Of the 345 eyes, 139 were treated with systemic chemoreduction (102 Group D, 37 Group E) and 206 with primary enucleation (63 Group D, 143 Group E). In the chemoreduction group, one patient developed metastasis (0.7%) and one an orbital recurrence (0.7%). In the primary enucleation group, two patients developed metastases (0.9%) and one an orbital recurrence (0.5%). After systemic chemoreduction, 58 of the 139 eyes (30 Group D, 28 Group E) were secondarily enucleated for treatment failure (41.7%). The median time to secondary enucleation from diagnosis was 8.1 months. None of the eyes in the systemic chemoreduction group had high-risk pathologic features. In the primary enucleation group, 56 eyes had high-risk pathology. CONCLUSION: Over a 20-year period, 345 eyes were treated for advanced retinoblastoma at Children's Hospital Los Angeles. Incidence of orbital recurrence and metastatic disease was <1% and did not vary by treatment modality or group classification. None of the eyes enucleated for treatment failure had high-risk pathology, and none of these patients developed metastatic disease. Globe salvage therapy with systemic chemoreduction and subsequent enucleation for poor response does not increase the risk of metastatic disease or orbital recurrence.
Authors: Carol L Shields; Fairooz P Manjandavida; Sara E Lally; Giulia Pieretti; Sruthi A Arepalli; Emi H Caywood; Pascal Jabbour; Jerry A Shields Journal: Ophthalmology Date: 2014-03-21 Impact factor: 12.079
Authors: Santosh G Honavar; Arun D Singh; Carol L Shields; Anna T Meadows; Hakan Demirci; Jacqueline Cater; Jerry A Shields Journal: Arch Ophthalmol Date: 2002-07
Authors: Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Saad Al-Dahmash; John P McLaughlin; Jerry A Shields; Ralph C Eagle Journal: Ophthalmology Date: 2013-02-08 Impact factor: 12.079
Authors: Pim de Graaf; Sophia Göricke; Firazia Rodjan; Paolo Galluzzi; Philippe Maeder; Jonas A Castelijns; Hervé J Brisse Journal: Pediatr Radiol Date: 2011-08-18
Authors: Jonathan E Lu; Jasmine H Francis; Ira J Dunkel; Carol L Shields; Michael D Yu; Jesse L Berry; Kaitlin Kogachi; Alison H Skalet; Audra K Miller; Pranav R Santapuram; Anthony B Daniels; David H Abramson Journal: Br J Ophthalmol Date: 2018-10-25 Impact factor: 4.638
Authors: Mary E Kim; Ashley Polski; Liya Xu; Rishvanth K Prabakar; Chen-Ching Peng; Mark W Reid; Rachana Shah; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry Journal: Cancers (Basel) Date: 2021-07-03 Impact factor: 6.639